2026-01-19 Microdose (industry)

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

An industry wide look at how neuroplastogens are reshaping psychedelic medicine in 2026, with insights on Delix, AbbVie’s Gilgamesh acquisition, Enveric, and the shift toward nonhallucinogenic brain therapeutics. The post Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative appeared first on Microdose.

External link. We are not responsible for the content.

Read more ↗

More From Microdose (industry)

2026-02-25 Microdose (industry)

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

In a development that could ripple across the fast evolving neuroplastogen sector, Enveric Biosciences announced that...

2026-02-19 Microdose (industry)

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

A new data release from Enveric Biosciences is sharpening the scientific debate at the heart of psychedelic drug deve...

2026-02-09 Microdose (industry)

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

For much of the last decade, psychedelic medicine has been driven by clinical outcomes first and mechanistic explanat...

Research

Latest News

2026-02-28 Chemical Collective

Comment perfectionner la préparation de son trip ?

La préparation d’un voyage est un processus à la fois intérieur et extérieur – qui consiste à aligner l’intention, l’...

2026-02-27 Lucid News

Authors of Largest Microdosing Study Suggest Benefits Limited To Dosing Day

Recent research surveying 1,435 microdosers suggests that microdosing’s duration of effect might be more like that of...

Microdosing Research
2026-02-27 The Microdose (Berkeley)

The FDA is changing the drug approval process; In a Senate hearing, Surgeon General nominee Casey Means was asked about psychedelics use

Plus: RAND survey shows that nearly a quarter of U.S. adults support legal use of psilocybin mushrooms; Reunion Neuro...

2026-02-27 Psychedelic Alpha

Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials

In this conversation with Psychedelic Alpha’s Josh Hardman, Dr. Terence Ching discusses his journey into the field an...

2026-02-27 Tripsitter (Substack)

Can Psychedelics Break the Consumption Cycle?

Consumer culture doesn’t just shape what we buy — it shapes what we want. Here’s why that’s harder to escape than you...

2026-02-27 The Psychedelic Blog (Substack)

Psychedelics Can Just Be for Fun

Welcome to the Psychedelic Blog. I write about the impact of Psychedelics on Grieving, Relationships, Culture & Death.